Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2020 2
2021 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.
Cheng M, Shao Y, Li L, Jiang M, Song Z. Cheng M, et al. BMC Cancer. 2024 Mar 6;24(1):312. doi: 10.1186/s12885-024-12043-w. BMC Cancer. 2024. PMID: 38448878 Free PMC article.
BACKGROUND: There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). ...The primary outcome was the cost-effectiveness analysis of …
BACKGROUND: There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung …
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.
Yu A, Huang E, Abe M, An K, Park SK, Park C. Yu A, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):381-393. doi: 10.1080/14737167.2021.1886928. Epub 2021 Feb 22. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33554675
Introduction: Mutation-targeting and immuno-oncology drugs are revolutionizing the treatment of advanced non-small cell lung cancer (NSCLC). Cost-effectiveness analyses (CEA) of these drugs have been conducted using various analytical methods and co …
Introduction: Mutation-targeting and immuno-oncology drugs are revolutionizing the treatment of advanced non-small cell lung c …
Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.
Bongers ML, Coupé VM, Jansma EP, Smit EF, Uyl-de Groot CA. Bongers ML, et al. Pharmacoeconomics. 2012 Jan;30(1):17-34. doi: 10.2165/11595000-000000000-00000. Pharmacoeconomics. 2012. PMID: 22201521 Review.
In past decades, studies focusing on new chemotherapeutic agents for patients with inoperable non-small-cell lung cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic evidence is lacking on sup …
In past decades, studies focusing on new chemotherapeutic agents for patients with inoperable non-small-cell lung cancer have …
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H, Xin W, Tong Y, Sun J, Xu G, Ye Z, Rao Y. Ding H, et al. PLoS One. 2020 Sep 2;15(9):e0238536. doi: 10.1371/journal.pone.0238536. eCollection 2020. PLoS One. 2020. PMID: 32877435 Free PMC article.
OBJECTIVES: The aim of this study was to evaluate the cost effectiveness of immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC). ...Results of the cost-effectiveness of atezolizumab second-line treatmen …
OBJECTIVES: The aim of this study was to evaluate the cost effectiveness of immune checkpoint inhibitors (ICIs) for treatment …
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
Simons MJHG, Retèl VP, Ramaekers BLT, Butter R, Mankor JM, Paats MS, Aerts JGJV, Mfumbilwa ZA, Roepman P, Coupé VMH, Uyl-de Groot CA, van Harten WH, Joore MA. Simons MJHG, et al. Pharmacoeconomics. 2021 Dec;39(12):1429-1442. doi: 10.1007/s40273-021-01073-y. Epub 2021 Aug 18. Pharmacoeconomics. 2021. PMID: 34405371 Free PMC article.
OBJECTIVE: The objective of this study was to determine the early cost effectiveness of using WGS in diagnostic strategies compared with currently used molecular diagnostics for patients with inoperable stage IIIB,C/IV non-squamous NSCLC from a Dutch healthca …
OBJECTIVE: The objective of this study was to determine the early cost effectiveness of using WGS in diagnostic strategies com …
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Brown T, et al. Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Health Technol Assess. 2013. PMID: 23886301 Free PMC article. Review.
This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently license …
This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. …
Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID era.
Gupta T, Ghosh-Laskar S, Agarwal JP. Gupta T, et al. Oral Oncol. 2020 Dec;111:105045. doi: 10.1016/j.oraloncology.2020.105045. Epub 2020 Oct 20. Oral Oncol. 2020. PMID: 33091846 Free PMC article.
The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing worldwide, with over three quarters of cases now diagnosed in low and middle-income countries (LMICs) with resource-constraints. ...The radiation oncology community has been systemat …
The incidence of head and neck squamous cell carcinoma (HNSCC) is increasing worldwide, with over three quarters of cas …